1 study found for:    15699478 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers
Conditions: Non-Small Cell Lung Neoplasms;   Prostate Neoplasms;   Bladder Neoplasms;   Ovarian Neoplasms;   Breast Neoplasms
Intervention: Drug: MGAH22

Indicates status has not been verified in more than two years